title: Determining vulnerability to schizophrenia in methamphetamine psychosis using exploratory eye movements.
abstract: Patients with methamphetamine (MAP) psychosis whose psychotic symptoms continued after MAP withdrawal were observed at Saitama Prefecture Government Psychiatric Hospital. The purpose of the present study was to ascertain whether some of these MAP psychosis subjects have a vulnerability to schizophrenia. Forty-eight patients with MAP psychosis were divided into three groups based on clinical course: transient type, prolonged type and persistent type. Furthermore, the patients with the persistent type were divided into two groups: one group were moderately disturbed in social adaptive functioning and had Global Assessment Functioning scale (GAF) points >50, and the other group consisted of those who were severely disturbed in social adaptive functioning and who had GAF points of < or =50. These MAP patients were tested for exploratory eye movements, which are the vulnerability marker of schizophrenia, and were compared with 30 patients with schizophrenia and 30 healthy control subjects. The responsive search score of the severely disturbed group of patients of the persistent type was lowest, significantly lower than those of the transient type and the healthy controls. It did not differ from that of the schizophrenic subjects. These results suggest that the severely disturbed group of patients with the persistent type of MAP psychosis have a vulnerability to schizophrenia.
authors.affiliation: Section of Psychiatry and Behavioral Science, Graduate School of Tokyo Medical and Dental University, Tokyo, Japan.
authors.forename: Tomoko
authors.initials: T
authors.lastname: Mikami
authors.forename: Nobuya
authors.initials: N
authors.lastname: Naruse
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Fukura
authors.forename: Hiromi
authors.initials: H
authors.lastname: Ohkubo
authors.forename: Tatsunobu
authors.initials: T
authors.lastname: Ohkubo
authors.forename: Masato
authors.initials: M
authors.lastname: Matsuura
authors.forename: Hirobumi
authors.initials: H
authors.lastname: Moriya
authors.forename: Toru
authors.initials: T
authors.lastname: Nishikawa
authors.forename: Takuya
authors.initials: T
authors.lastname: Kojima
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D004493:Education; D005106:Exploratory Behavior / Q000502:physiology*; D005133:Eye Movements / Q000187:drug effects / Q000502:physiology*; D005260:Female; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D011569:Psychiatric Status Rating Scales; D011605:Psychoses, Substance-Induced / Q000175:diagnosis* / Q000453:epidemiology / Q000523:psychology; D012559:Schizophrenia / Q000175:diagnosis* / Q000453:epidemiology; D012565:Schizophrenic Psychology; D012737:Sex Factors
chemical_list: D014150:Antipsychotic Agents